The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.

From February 8th article on HIV.gov: https://www.hiv.gov/blog/update-covid-19-treatment-guidelines-changes-affecting-people-hiv?utm_source=email&utm_medium=email&utm_campaign=weekly20220207&utm_content=federalresponse :

The Panel (COVID-19 Treatment Guidelines Panel) periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the appropriate sections of the Guidelines.

Key changes specific to people with HIV include:

• The Panel notes that people with advanced or untreated HIV who do not have SARS-CoV-2 infection and who have not been recently exposed to SARS-CoV-2 are eligible to receive tixagevimab plus cilgavimab as pre-exposure prophylaxis for SARS-CoV-2.

• People with HIV who are on ritonavir- or cobicistat-based antiretroviral (ARV) regimens and who are prescribed ritonavir-boosted nirmatrelvir (Paxlovid) for the treatment of COVID-19 can continue their ARV regimens without dosage modifications

For a complete list of updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.